Certara Creates Global Strategic Modeling and Simulation Consultancy
Certara®, a global biosimulation technology-enabled drug development company, announced the merger of its consulting group, Pharsight Consulting Services.
Certara®, a global biosimulation technology-enabled drug development company, announced the merger of its consulting group, Pharsight Consulting Services (PCS), with Quantitative Solutions, a global pharmacometrics consulting company headquartered in Menlo Park, Calif. The resulting organization is called Certara Strategic Consulting.
This transaction increases Certara’s broadens the company’s modeling capabilities by adding model-based meta-analysis (MBMA) – which uses highly-curated clinical trial data and parametric pharmacology models to increase drug development productivity, quantitatively inform portfolio management, and improve clinical trial success. Another asset is the clinical outcomes databases for analyzing the comparative effectiveness of a new drug within its competitive landscape. Certara has four business units – Certara Strategic Consulting, Certara Software, Simcyp (which focuses on PBPK), and Synchrogenix (which specializes in regulatory writing).
Read the full release here.
Behind the Buzz: Why Clinical Research Leaders Flock to SCOPE Summit
February 7th 2025In this episode, we meet with Micah Lieberman, Executive Conference Director for SCOPE Summit (Summit for Clinical Ops Executives) at Cambridge Innovation Institute. We will dive deep into the critical role of collaboration within the clinical research ecosystem. How do we bring together diverse stakeholders—sponsors, CROs, clinical trial tech innovators, suppliers, patients, sites, advocacy organizations, investors, and non-profits—to share best practices in trial design, program planning, innovation, and clinical operations? We’ll explore why it’s vital for thought leaders to step beyond their own organizations and learn from others, exchanging ideas that drive advancements in clinical research. Additionally, we’ll discuss the pivotal role of scientific conferences like SCOPE Summit in fostering these essential connections and collaborations, helping shape the future of clinical trials. Join us as we uncover how collective wisdom and cross-industry partnerships are transforming the landscape of clinical research.
Reaching Diverse Patient Populations With Personalized Treatment Methods
January 20th 2025Daejin Abidoye, head of solid tumors, oncology development, AbbVie, discusses a number of topics around diversity in clinical research including industry’s greatest challenges in reaching diverse patient populations, personalized treatment methods, recruitment strategies, and more.
POETYK PsA-2 Trial Shows Efficacy of Sotyktu as an Oral Therapy for Psoriatic Arthritis
March 11th 2025Sotyktu (deucravacitinib) demonstrated significant efficacy in improving psoriatic arthritis symptoms compared to placebo in the Phase III POETYK PsA-2 trial, with a well-tolerated safety profile.
